Clinical Validity Of Circulating Tumor Cells (CTC)
Assessment of Clinical Validity of Circulating Tumor Cells (CTC) Quantification
Clinical Validity Of Circulating Tumor Cells (CTC) In Patients With Metastatic Breast Cancer: A Pooled Analysis of Individual Patient Data
The purpose was to assess the clinical validity of circulating tumor cells (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data. IDDI performed this statistical analysis.
These data confirmed the independent prognostic effect of CTC count on progression-free survival and overall survival. This is the first study to show that CTC count also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumor markers do not.